Adalimumab: a review of the reference product and biosimilars

References

• Lis K, Kuzawińska O, Bałkowiec-Iskra E. State of the art paper tumor necrosis factor inhibitors – state of knowledge. Arch Med Sci. 2014;6:1175–1185.
   Web of Science ®Google Scholar
• Agarwal SK. Biologic agents in rheumatoid arthritis: an update for managed care professionals. J Manag Care Pharm. 2011;17(9 Suppl B):14–18.
   PubMed Web of Science ®Google Scholar
• Ma X, Xu S. TNF inhibitor therapy for rheumatoid arthritis. Biomed Rep. 2013;1(2):177–184.
   PubMedGoogle Scholar
• Dörner T, Strand V, Castañeda-Hernández G, Ferraccioli G, Isaacs JD, Kvien TK, et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis. 2013;72(3):322–328.
   PubMed Web of Science ®Google Scholar
• Schneider CK. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis. 2013;72(3):315–318.
   PubMed Web of Science ®Google Scholar
• Balzola F, Cullen G, Hoentjen F, Ho GT, Russell R. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Inflamm Bowel Dis Monit. 2013;13:162.
   Google Scholar
• Abbot Imunology [webpage on the Internet]. The Humira Story or “How D2E7 Became a Star” 2013. Available from: http://www.phagedisplay.org/pdfs/Kamen_TheHumirastory.pdf. Accessed April 2015.
   Google Scholar
• FiercePharma [webpage on the Internet]. Humira biosimilars will gut AbbVie’s sales in 3 years 2015. Available from: http://www.fiercepharma.com/story/humira-biosimilars-will-gut-abbvies-sales-3-years-analyst-says/2015-02-10. Accessed March 2015.
   Google Scholar
• European Medicines Agency [webpage on the Internet]. Scientific discussion for the approval of Humira. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000481/WC500050867.pdf. Accessed April 2, 2015.
   Google Scholar
• AbbVie [webpage on the Internet]. A new beginning. Available from: http://www.abbvie.com/about-us/who-we-are.html. Accessed February 2015.
   Google Scholar
• Möller A, Emling F, Blohm D, Schlick E, Schollmeier K. Monoclonal antibodies to human tumor necrosis factor alpha: in vitro and in vivo application. Cytokine. 1990;2(3):162–169.
   PubMedGoogle Scholar
• Keffer J, Probert L, Caziaris H, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991;10(13):4025–4031.
   PubMed Web of Science ®Google Scholar
• Kempeni J. Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7. Ann Rheum Dis. 1999;58(Suppl 1):170–172.
   Google Scholar
• Kazuo I [webpage on the Internet]. United States Patent and Trademark Office. Available from: http://www.uspto.gov/sites/default/files/web/offices/pac/dapp/opla/term/certs/6090382.pdf. Accessed February 2015.
   Google Scholar
• Siddiqui Z [webpage on the Internet]. India’s Cadila launches first cheaper copy of world’s top-selling drug 2014. Available from: http://www.reuters.com/article/2014/12/09/us-cadila-health-humira-india-idUSKBN0JN0X820141209. Accessed February 2015.
   Google Scholar
• U.S. Food and Drug Administration [webpage on the Internet]. Adalimumab Product Approval Information – Licensing Action. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080610.htm. Accessed February 2015.
   Google Scholar
• European Medicines Agency [webpage on the Internet]. Anexo I – Resumo das Características do Medicamento: Humira 2010:1–29. Available from: http://www.ema.europa.eu/docs/pt_PT/document_library/EPAR_-_Product_Information/human/000481/WC500050870.pdf. Accessed April 2015.
   Google Scholar
• Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48(1):35–45.
   PubMed Web of Science ®Google Scholar
• Van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004;63(5):508–516.
   PubMed Web of Science ®Google Scholar
• Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled. Arthritis Rheum. 2004;50(5):1400–1411.
   PubMed Web of Science ®Google Scholar
• Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 2003;30(12):2563–2571.
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previo. Arthritis Rheum. 2006;54(1):26–37.
   PubMed Web of Science ®Google Scholar
• U S Food and Drug Administration [webpage on the Internet]. FDA approves Humira to treat ulcerative colitis. FDA News Release 2012. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm321650.htm. Accessed January 2015.
   Google Scholar
• Mease PJ, Gladman DD, Ritchlin CT, et al; Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52(10):3279–3289.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Mease PJ, Choy EH, Ritchlin CT, Perdok RJ, Sasso EH. Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. Arthritis Res Ther. 2010;12(3):R113.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Mease PJ, Thomson GT, et al; M02-570 Study Group. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol. 2007;34(5):1040–1050.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55(4):598–606.
   PubMed Web of Science ®Google Scholar
• Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106–115.
   PubMed Web of Science ®Google Scholar
• Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158(3):558–566.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Langley RG, Papp K, et al. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol. 2011;147(4):429–436.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Bolduc C, Poulin Y, Guenther L, Lynde CW, Maari C. Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept. J Am Acad Dermatol. 2010;63(2):228–234.
   PubMed Web of Science ®Google Scholar
• Van Lümig PP, Lecluse LL, Driessen RJ, et al. Switching from etanercept to adalimumab is effective and safe: Results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept. Br J Dermatol. 2010;163(4):838–846.
   PubMed Web of Science ®Google Scholar
• Gorman JD, Sack KE, Davis JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002;346(18):1349–1356.
   PubMed Web of Science ®Google Scholar
• Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 2003;48(6):1667–1675.
   PubMed Web of Science ®Google Scholar
• Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002;359(9313):1187–1193.
   PubMed Web of Science ®Google Scholar
• Braun J, Brandt J, Listing J, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum. 2003;48(8):2224–2233.
   PubMed Web of Science ®Google Scholar
• Van Der Heijde D, Dijkmans B, Geusens P, et al; Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52(2):582–591.
   PubMed Web of Science ®Google Scholar
• Haibel H, Rudwaleit M, Listing J, et al. Efficacy of adalimumab in the treatment of axial spondyloarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum. 2008;58(7):1981–1991.
   PubMed Web of Science ®Google Scholar
• Lambert RGW, Salonen D, Rahman P, et al. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: A multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2007;56(12):4005–4014.
   PubMed Web of Science ®Google Scholar
• Van Der Heijde D, Kivitz A, Schiff MH, et al; ATLAS Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54(7):2136–2146.
   PubMed Web of Science ®Google Scholar
• U S Food and Drug Administration [webpage on the Internet]. FDA Approves New Treatment For Crohn’s Disease. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108852.htm. Accessed April 2015.
   Google Scholar
• European Medicines Agency [webpage on the Internet]. Assessment report: Humira 2012;44:3–65. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000481/WC500133080.pdf. Accessed April 2015.
   Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: The CLASSIC-I trial. Gastroenterology. 2006;130(2):323–332.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132(1):52.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146(12):829–838.
   PubMed Web of Science ®Google Scholar
• Hyams JS, Markowitz J, Baldassano RN, et al. Safety and efficacy of adalimumab for moderate to severe Crohn’s disease in children. Gastroenterology. 2012;143(2):365–374.e2.
   Web of Science ®Google Scholar
• Rosenbach Y, Hartman C, Shapiro R, Hirsch A, Avitzur Y, Shamir R. Adalimumab treatment in children with refractory Crohn’s disease. Dig Dis Sci. 2010;55(3):747–753.
   PubMed Web of Science ®Google Scholar
• AbbVie’s. HUMIRA® (adalimumab) receives U.S. FDA approval for extension of polyarticular juvenile idiopathic arthritis indication to patients ages 2 and older 2014. Available from: http://www.prnewswire.com/news-releases/abbvies-humira-adalimumab-receives-us-fda-approval-for-extension-of-polyarticular-juvenile-idiopathic-arthritis-indication-to-patients-ages-2-and-older-278214991.html. Accessed February 2015.
   Google Scholar
• Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810–820.
   PubMed Web of Science ®Google Scholar
• Kingsbury DJ, Bader-Meunier B, Patel G, Arora V, Kalabic J, Kupper H. Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years. Clin Rheumatol. 2014;33(10):1433–1441.
   PubMed Web of Science ®Google Scholar
• Edelsten C, Reddy MA, Stanford MR, Graham EM. Visual loss associated with pediatric uveitis in English primary and referral centers. Am J Ophthalmol. 2003;135(5):676–680.
   PubMed Web of Science ®Google Scholar
• Smith JA, Mackensen F, Sen HN, et al. Epidemiology and course of disease in childhood uveitis. Ophthalmology. 2009;116(8):1544–1551.
   PubMed Web of Science ®Google Scholar
• De Boer J, Wulffraat N, Rothova A. Visual loss in uveitis of childhood. Br J Ophthalmol. 2003;87(7):879–884.
   PubMed Web of Science ®Google Scholar
• Dick AD, Forrester JV, Liversidge J, Cope AP. The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Prog Retin Eye Res. 2004;23(6):617–637.
   PubMed Web of Science ®Google Scholar
• AbbVie GK [webpage on the Internet]. AbbVie and Eisai Announce HUMIRA® Pre-filled Syringe Has Received Approval for the Treatment of Intestinal Behçet’s Disease in Japan 2013. Available from: http://www.eisai.com/news/enews201330pdf.pdf. Accessed April 2015.
   Google Scholar
• Tanida S, Inoue N, Kobayashi K, et al. Adalimumab for the treatment of Japanese patients with intestinal Behçet’s diseases. Clin Gastroenterol Hepatol. 2014;13(5):940–948.
   Web of Science ®Google Scholar
• U S Food and Drug Administration [webpage on the Internet]. FDA approves Humira to treat ulcerative colitis. FDA News Release 2012. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm321650.htm. Accessed April 2015.
   Google Scholar
• European Medicines Agency EMA [webpage on the Internet]. Humira: EPAR summary for the public 2013. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000481/WC500050865.pdf. Accessed April 2015.
   Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60(6):780–787.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(2):257–265.e1–.e3.
   Web of Science ®Google Scholar
• Bang LM, Keating GM. Adalimumab: a review of its use in rheumatoid arthritis. BioDrugs. 2004;18(2):121–139.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48(1):35–45.
   PubMed Web of Science ®Google Scholar
• Weisman MH, Moreland LW, Furst DE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003;25(6):1700–1721.
   PubMed Web of Science ®Google Scholar
• Warner B, Harris AW. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;143(1):e42; author reply e42. Epub 2012 May 24.
   Web of Science ®Google Scholar
• Mease PJ. Adalimumab in the treatment of arthritis. Ther Clin Risk Manag. 2007;3:133–148.
   PubMedGoogle Scholar
• Vena GA, Cassano N. Drug focus: adalimumab in the treatment of moderate to severe psoriasis. Biologics. 2007;1(2):93–103.
   PubMedGoogle Scholar
• Cassinotti A, Ardizzone A, Porro GB. Adalimumab for the treatment of Crohn ’ s disease. Biologics. 2008;2(4):763–777.
   PubMedGoogle Scholar
• Shen C, Assche GV, Colpaert S, et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther. 2005;21(3):251–258.
   PubMed Web of Science ®Google Scholar
• Shen C, Van Assche G, Rutgeerts P, Ceuppens JL. Caspase activation and apoptosis induction by adalimumab: demonstration in vitro and in vivo in a chimeric mouse model. Inflamm Bowel Dis. 2006;12(1):22–28.
   PubMed Web of Science ®Google Scholar
• Michel MH, Moreland LW, Furst DE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003;25(6):1700–1721.
   Web of Science ®Google Scholar
• Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum. 2005;34(5 Suppl 1):12–18.
   PubMed Web of Science ®Google Scholar
• Machado MA, Maciel AA, Lemos LL, et al. Adalimumabe no tratamento da artrite reumatoide: uma revisão sistemática e metanálise de ensaios clínicos randomizados [Adalimumab in rheumatoid arthritis treatment: a systematic review and meta-analysis of randomized clinical trials]. Rev Bras Reumatol. 2013;53:419–430. Portuguese.
   PubMedGoogle Scholar
• Brunton L, Chabner B, Bruce AB, Knollman B. Goodman Gilman’s Pharmacol. Basis of Therapeutics. 12th ed. New York, NY: McGraw Hill Education; 2010.
   Google Scholar
• Granneman RG, Zhang Y, Noertersheuser PA, Velagapudi RB, Awni WM. Pharmacokinetic/pharmacodynamic (PK/PD) relationships of adalimumab (HUMIRATM) in rheumatoid arthritis (RA) patients during phase II/III clinical trials. In: ACR Annual Scientific Meeting; November 2003; Orlando. Poster 256.
   Google Scholar
• Velagapudi RB. The effect of methotrexate (MTX) coadministration on the pharmacokinetics (PK) of adalimumab (HUMIRATM) following a single intravenous injection to rheumatoid arthritis patients. In: ACR Annual Scientific Meeting; November 2003; Orlando. Poster 258.
   Google Scholar
• Chen DM, Gordon KB, Leonardi CM. Adalimumab efficacy and safety in patients with moderate to severe chronic plaque psoriasis: preliminary findings from a 12-week dose ranging trial. J Am Acad Dermatol. 2004;50:491.
   Web of Science ®Google Scholar
• Kneepkens EL, Wei JC, Nurmohamed MT, et al. Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up. Ann Rheum Dis. 2013;74(2):396–401.
   Web of Science ®Google Scholar
• Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305(14):1460–1468.
   PubMed Web of Science ®Google Scholar
• Vogelzang EH, Kneepkens EL, Nurmohamed MT, et al. Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up. Ann Rheum Dis. 2014;73(12):2178–2182.
   PubMed Web of Science ®Google Scholar
• Pouw MF, Krieckaert CL, Nurmohamed MT, et al. Key findings towards optimising adalimumab treatment: the concentration-effect curve. Ann Rheum Dis. 2015;74(3):513–518.
   PubMed Web of Science ®Google Scholar
• Burmester G-R, Kivitz AJ, Kupper H, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis. 2015;74(6):1037–1044.
   PubMed Web of Science ®Google Scholar
• Mease PJ. Spondyloarthritis: is methotrexate effective in psoriatic arthritis? Nat Rev Rheumatol. 2012;8(5):251–252.
   PubMed Web of Science ®Google Scholar
• Jani M, Chinoy H, Warrens R, Griffiths C, Barton A. Effect of immunogenicity on efficacy of long-term treatment of rheumatoid arthritis with adalimumab. Lancet. 2014;68:1–16.
   Google Scholar
• Krieckaert CL, Nair SC, Nurmohamed MT, et al. Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects. Ann Rheum Dis. 2015;74(2):361–368.
   PubMed Web of Science ®Google Scholar
• World Health Organization [webpage on the Internet]. Pharmacovigilance guidelines 2010. Available from: http://www.who.int/medicines/areas/quality_safety/safety_efficacy/S.AfricaDraftGuidelines.pdf. Accessed December 2014.
   Google Scholar
• European Medicines Agency [webpage on the Internet]. Guidelines on good pharmacovigilance practices 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/05/WC500143294.pdf. Accessed April 2015.
   Google Scholar
• U S Food and Drug Administration [webpage on the Internet]. FDA and European Medicines Agency strengthen collaboration in pharmacovigilance area; 2014. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm386372.htm. Accessed December 2014.
   Google Scholar
• Lionetti G, Kimura Y, Schanberg LE, et al. Using registries to identify adverse events in rheumatic diseases. Pediatrics. 2013;132(5):e1384–e1394.
   Web of Science ®Google Scholar
• Martin L, Barnabe C [webpage on the Internet]. 15 Years of Managing Rheumatoid Arthritis in Alberta with Biologic Therapies: Program Infrastructure, Efficacy, Safety and Health Economics. Available from: http://www.departmentofmedicine.com/rounds/presentations/2014/managing_arthritis_alberta.pdf. Accessed December 2014.
   Google Scholar
• Humira [webpage on the Internet]. My Humira. Available from: https://www.humira.com/global/starting-humira. Accessed December 2014.
   Google Scholar
• U S Food and Drug Administration [webpage on the Internet]. Adverse events redefining drug safety 2014. Available from: http://adverseevents.com/research.php. Accessed December 2014.
   Google Scholar
• Pediatric Advisory Committee [webpage on the Internet]. Pediatric Postmarketing Adverse Event review 2009:2–16. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM191899.pdf. Accessed December 2014.
   Google Scholar
• Mendes D, Alves C, Batel-Marques F. Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events. J Clin Pharm Ther. 2014;39(3):307–313.
   Web of Science ®Google Scholar
• U S Food and Drug Administration [webpage on the Internet]. FDA Approves Humira to treat ulcerative colitis. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm321650.htm. Accessed April 2015.
   Google Scholar
• Bartelds GM, Krieckaret CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305(14):1460–1468.
   PubMed Web of Science ®Google Scholar
• Kumar R, Singh J. Biosimilar drugs: current status. Int J Appl Basic Med Res. 2014;4(2):63–66.
   PubMedGoogle Scholar
• Martínez de Lagrán Z, Pérez-Barrio S, Díaz-Pérez JL. Adalimumab : la molécula y el proceso de obtención. Actas Dermosifiliogr. 2008;99:3–9.
   Google Scholar
• Azzazy HM, Highsmith WE. Phage display technology: clinical applications and recent innovations. Clin Bio Chem. 2002;35(6):425–445.
   PubMed Web of Science ®Google Scholar
• Hoogenboom HR, de Bruine AP, Hufton SE, Hoet RM, Arends JW, Roovers RC. Antibody phage display techno- logy and its applications. Immunotechnology. 1998;4(1):1–20.
   PubMedGoogle Scholar
• Vispo NS, Yaquelin P. Bacteriófagos: de la terapia con fagos a la biología combinatoria. Biotecnología aplicada. 2001;18:135–147.
   Google Scholar
• George A. HUMIRA manufacturing: challenges and the path taken. GAb Abstr. 2004;3:15–17.
   Google Scholar
• Raju ST. Glycosylation variations with expression systems and their impact on biological activity of therapeutic immunoglobulins. Bioprocess Int. 2003;1:44–51.
   Google Scholar
• Umana P, Jean-Mairet J, Bailey JE. Tetracycline-regulated overexpression of glycosyltransferases in Chinese hamster ovary cells. Biotechnol Bioeng. 1999;65(5):542–549.
   Web of Science ®Google Scholar
• Pimentel V, Gomes R [webpage on the Internet]. O desafio de adensar a cadeia de P & D de medicamentos biotecnológicos no Brasil 2010. Available from: http://www.bndes.gov.br/SiteBNDES/export/sites/default/bndes_pt/Galerias/Arquivos/conhecimento/bnset/set3805.pdf. Accessed April 2015.
   Google Scholar
• Rodrigues ME, Costa AR, Henriques M, Azeredo J, Oliveira R. Technological progresses in monoclonal antibody production systems. Biotechnol Prog. 2009;26(2):332–351.
   Web of Science ®Google Scholar
• Rathore AS, Reason AJ, Weiskopf A. Defining critical quality attributes for monoclonal antibody therapeutic products. Bio Pharm Int. 2014;27(7):34–43.
   Google Scholar
• European Medicines Agency [webpage on the Internet]. Guideline on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf. Accessed April 2015.
   Google Scholar
• Beck A, Riechert JM. Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry. MAbs. 2013;5(5):621–623.
   PubMed Web of Science ®Google Scholar
• Burki TK. First biosimilar drug approved in the USA. Lancet Oncol. 2015;16:161.
   Web of Science ®Google Scholar
• Central Drugs Standard Control Organization (CDSCO). Guidelines on Similar Biologics: Regulatory Requirements for Marketing Authorization in India; 2012. Available from: http://dbtbiosafety.nic.in/Files%5CCDSCO-DBTSimilarBiologicsfinal.pdf. Accessed May 2015.
   Google Scholar
• Azevedo VF. Biosimilars require scientifically reliable comparative clinical data. Rev Bras Reum. 2013;53(1):129–131.
   PubMedGoogle Scholar
• Lee H. Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars? AAPS J. 2014;16(1):22–26.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2015. MAbs. 2015;7(1):1–8.
   PubMed Web of Science ®Google Scholar
• Amgen [webpage on the Internet]. Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate ABP 501 Compared With Adalimumab In Patients With Moderate-To-Severe Plaque Psoriasis. Available from: http://www.amgen.com/media/media_pr_detail.jsp?releaseID=1975377. Accessed May 2015.
   Google Scholar
• GaBi Online [webpage on the Internet]. Amgen to start phase III trial for biosimilar adalimumab; 2013. Available from: http://gabionline.net/Biosimilars/News/Amgen-to-start-phase-III-trial-for-biosimilar-adalimumab. Accessed February 2015.
   Google Scholar
• Clinical Trials [webpage on the Internet]. Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (Humira®) in Adults With Moderate to Severe Plaque Psoriasis 2014. Available from: http://clinicaltrials.gov/ct2/show/NCT01970488. Accessed March 2015.
   Google Scholar
• Clinical Trials [webpage on the Internet]. Pharmacokinetics and safety study of BI 695501 in healthy subjects. Available from: http://clinicaltrials.gov/ct2/show/NCT01505491?term=BI+695501&rank=1. Accessed February 2015.
   Google Scholar
• GaBi Online [webpage on the Internet]. Boehringer Ingelheim completes biosimilar adalimumab trial 2012. Available from: http://www.gabionline.net/Biosimilars/Research/Boehringer-Ingelheim-completes-biosimilar-adalimumab-trial. Accessed February 2015.
   Google Scholar
• Boehringer Ingelheim [homepage on the Internet]. Available from: https://www.boehringer-ingelheim.com/research_development/drug_discovery/pipeline.html. Accessed February 2015.
   Google Scholar
• Clinical Trials [webpage on the Internet]. Pfizer to start trial for biosimilar adalimumab; 2013. Available from: www.gabionline.net/Biosimilars/News/Pfizer-to-start-trial-for-biosimilar-adalimumab. Accessed February 2015.
   Google Scholar
• GaBi Online [webpage on the Internet]. Adalimumab biosimilar has comparable pharmacokinetics to Humira. Available from: http://gabionline.net/layout/set/print/Biosimilars/Research/Adalimumab-biosimilar-has-comparable-pharmacokinetics-to-Humira. Accessed February 2015.
   Google Scholar
• Clinical Trials [webpage on the Internet]. Study of PF-06410293 and adalimumab in healthy subjects (REFLECTIONS B538-01). Available from: http://clinicaltrials.gov/ct2/show/NCT01870986?term=to+PF-06410293&rank=1. Accessed February 2015.
   Google Scholar
• Sandoz [webpage on the Internet]. Sandoz begins Phase II clinical trials for biosimilar adalimumab. Available from: www.biosimilarnews.com/sandoz-begins-phase-iii-clinical-trial-for-biosimilar-adalimumab. Accessed February 2015.
   Google Scholar
• Clinical Trials [webpage on the Internet]. Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira (ADACCESS). Available from: https://clinicaltrials.gov/ct2/show/NCT02016105?term=gp2017&rank=1. Accessed February 2015.
   Google Scholar
• Kronthaler U, Hexal AG, Silva A, Poetzl J, Seliskar M. Similar preclinical pharmacokinetics of the proposed biosimilar adalimumab GP2017 and originator adalimumab upon single and multiple administrations. J Am Acad Dermatol. 2014;70(5):190.
   Web of Science ®Google Scholar
• Clinical Trials [webpage on the Internet]. A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy. Available from: http://www.clinicaltrials.gov/ct2/show/NCT02167139?term=biosimilar&recr=Open&no_unk=Y&rank=8. Accessed February 2015.
   Google Scholar
• Clinicaltrials.gov [webpage on the Internet]. A Study to Compare FKB327 Efficacy and Safety With Humira® in Rheumatoid Arthritis Patients (ARABESC). Available from: https://www.clinicaltrials.gov/ct2/show/NCT02260791. Accessed February 2015.
   Google Scholar
• BioSpectrum Asia [webpage on the Internet]. India firm launches biosimilar for autoimmune disease 2014. Available from: http://www.biospectrumasia.com/biospectrum/news/219784/india-firm-launches-biosimilar-autoimmune-disease. Accessed March 2015.
   Google Scholar
• GaBi Online [webpage on the Internet]. Adalimumab similar biologic launched in India. Available from: http://www.gabionline.net/layout/set/print/Biosimilars/News/Adalimumab-similar-biologic-launched-in-India. Accessed February 2015.
   Google Scholar
• Scott BJ, Klein AV, Wang J. Biosimilar monoclonal antibodies: a Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation. J Clin Pharmacol. 2015;55(Suppl 3):123–132.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Choquette D, Ghosh S, et al. The challenge of indication extrapolation for infliximab biosimilars. Biologicals. 2014;42(4):177–183.
   PubMed Web of Science ®Google Scholar
• Ebbers HC. Biosimilars: in support of extrapolation of indications. J Crohns Colitis. 2014;8(5):431–435.
   PubMed Web of Science ®Google Scholar
• Simoens S. Biosimilar medicines and cost-effectiveness. Clinicoecon Outcomes Res. 2011;3:29–36.
   PubMedGoogle Scholar
• Mendes de Abreu M, Strand V, Levy RA, Araujo DV. Putting the value into biosimilar decision making: the judgment value criteria. Autoimmun Rev. 2014;13(6):678–684.
   Web of Science ®Google Scholar
• Blackstone EA, Fuhr JP. Innovation and competition: will biosimilars succeed? Biotechnol Healthc. 2012;9(1):24–27.
   PubMedGoogle Scholar
• Ventola CL. Biosimilars part 1: proposed regulatory criteria for FDA approval. P T. 2013;38(5):270–287.
   PubMedGoogle Scholar
• Blackstone EA, Fuhr JP. The economics of biosimilars. Am Heal Drug Benefits. 2013;6(8):469–478.
   PubMedGoogle Scholar
• Sola RJ, Griebenow K. Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy. BioDrugs. 2010;24(1):9–21.
   PubMed Web of Science ®Google Scholar
• Fiorino G, Girolomoni G, Lapadula G, et al. The use of biosimilars in immune-mediated disease: a joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. Autoimmun Rev. 2014;13(7):751–755.
   PubMed Web of Science ®Google Scholar
• Azevedo VF, de Souza Meirelles E, Kochen Jde A, et al. Recommendations on the use of biosimilars by the Brazilian Society of Rheumatology, Brazilian Society of Dermatology, Brazilian Federation of Gastroenterology and Brazilian Study Group on Inflammatory Bowel Disease-Focus on clinical evaluation of monoclonal antibodies and fusion proteins used in the treatment of autoimmune diseases. Autoimmun Rev. 2015;14(9):769–773.
   Web of Science ®Google Scholar
• GaBi Online [webpage on the Internet]. The latest biosimilars agreements; 2014. Available from: www.gabionline.net/Biosimilars/News/The-latest-biosimilars-agreements. Accessed February 2015.
   Google Scholar
• GaBi Online [webpage on the Internet]. Fujifilm and Kyowa launch biosimilars joint venture 2014. Available from: www.gabionline.net/Biosimilars/News/Fujifilm-and-Kyowa-launch-biosimilars-joint-venture. Accessed February 2015.
   Google Scholar
• GaBi Online [webpage on the Internet]. Baxter and Momenta make biosimilars deal 2014. Available from: www.gabionline.net/Biosimilars/News/Baxter-and-Momenta-make-biosimilars-deal. Accessed February 2015.
   Google Scholar
• GaBi Online [webpage on the Internet]. Oncobiologics and Viropro make biosimilar deal 2014. Available from: www.gabionline.net/Biosimilars/News/Oncobiologics-and-Viropro-make-biosimilar-deal. Accessed February 2015.
   Google Scholar
• NOMURA [webpage on the Internet]. Korean Biopharmaceuticals. Coming of age: generics-centred players flourishing, preparing to go global. Available from: http://www.nomura.com/europe/resources/upload/Korean_biopharmaceuticals.pdf. Accessed February 2015.
   Google Scholar
• GaBi Online [webpage on the Internet]. Adalimumab biosimilar has comparable pharmacokinetics to Humira 2014. Available from: http://www.gabionline.net/layout/set/print/Biosimilars/Research/Adalimumab-biosimilar-has-comparable-pharmacokinetics-to-Humira. Accessed April 2015.
   Google Scholar
• Clinical Trials [webpage on the Internet]. A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects 2014. Available from: https://clinicaltrials.gov/ct2/show/NCT02237729. Accessed April 2015.
   Google Scholar
• Clinical Trials [webpage on the Internet]. A Study to Compare FKB327 Efficacy and Safety With Humira® in Rheumatoid Arthritis Patients 2014. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02260791. Accessed April 2015.
   Google Scholar